Gland Pharma logo

GLAND - Gland Pharma Share Price

₹2532.85 -49.3  -1.9%

Last Trade - 13/04/21

Large Cap
Market Cap £4.02bn
Enterprise Value £3.87bn
Revenue £377.4m
Position in Universe 91st / 3106
Unlock GLAND Revenue
Relative Strength (%)
1m +6.82%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -9.02%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Mar 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 0.000 0.000 16,229 20,442 26,332 34,027 40,141 +27.4%
+33.5 +63.3 +28.6 +22.9
Balance Sheet
FINANCIAL BRIEF: : For the nine months ended 31 December 2020, GlandPharma Ltd revenues increased 95% to RS25.75B. Net incomeincreased from RS3.38B to RS7.37B. Revenues reflect anincrease in demand for the Company's products and servicesdue to favorable market conditions. Net income benefitedfrom Other Rev from Biz Related Activ increase fromRS252.9M to RS875.6M (income), Interest Exp-Net ofCapitalized Interest decrease of 58% to RS23.9M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


GLAND Revenue Unlock GLAND Revenue

Net Income

GLAND Net Income Unlock GLAND Revenue

Normalised EPS

GLAND Normalised EPS Unlock GLAND Revenue

PE Ratio Range

GLAND PE Ratio Range Unlock GLAND Revenue

Dividend Yield Range

GLAND Dividend Yield Range Unlock GLAND Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
GLAND EPS Forecasts Unlock GLAND Revenue
Profile Summary

Gland Pharma Limited is an India-based company that manufactures small volume parenterals (SVPs). The Company provides a range of injectables including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions and ophthalmic solutions. It provides contract development and manufacturing services, such as evaluation of development needs, identifying application program interface (API) sources, analytical method development, formulation development and product / technology know-how; and manufacturing of registration batches, studies, dossier compilation for regulatory submission and commercial production. The Company’s therapeutic categories include Anti-Infectives, Anaesthetics, Anti-Coagulants and their Antidotes, Anti-Malarial, Cardiology, Gastro-Intestinal, Pain Management, Orthopaedics, Haematinics, Hormones and Related Drugs, Fertility Supplements, and Gnrh Agonists and Antagonists.

Last Annual March 31st, 2020
Last Interim December 31st, 2020
Incorporated March 20, 1978
No. of Shareholders: n/a
No. of Employees: 3,766
Sector Healthcare
Industry Pharmaceuticals
Exchange National Stock Exchange of India
Shares in Issue 163,592,923
Free Float (0.0%)
Eligible for
GLAND Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for GLAND
Upcoming Events for GLAND
Frequently Asked Questions for Gland Pharma
What is the Gland Pharma share price?

As of 13/04/21, shares in Gland Pharma are trading at ₹2532.85, giving the company a market capitalisation of £4.02bn. This share price information is delayed by 15 minutes.

How has the Gland Pharma share price performed this year?

Shares in Gland Pharma are currently trading at ₹2532.85 and the price has moved by % over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Gland Pharma price has moved by % over the past year.

What are the analyst and broker recommendations for Gland Pharma?

There are no analysts currently covering Gland Pharma.

When will Gland Pharma next release its financial results?

Gland Pharma is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Gland Pharma dividend yield?

Gland Pharma does not currently pay a dividend.

Does Gland Pharma pay a dividend?

Gland Pharma does not currently pay a dividend.

When does Gland Pharma next pay dividends?

Gland Pharma does not currently pay a dividend.

How do I buy Gland Pharma shares?

To buy shares in Gland Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Gland Pharma?

Shares in Gland Pharma are currently trading at ₹2532.85, giving the company a market capitalisation of £4.02bn.

Where are Gland Pharma shares listed? Where are Gland Pharma shares listed?

Here are the trading details for Gland Pharma:

Country of listing: India
Exchange: NSI
Ticker Symbol: GLAND
What kind of share is Gland Pharma?

Based on an overall assessment of its quality, value and momentum, Gland Pharma is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Gland Pharma share price forecast 2021?

Shares in Gland Pharma are currently priced at ₹2532.85. At that level they are trading at 2.62% discount to the analyst consensus target price of 0.00.

Analysts covering Gland Pharma currently have a consensus Earnings Per Share (EPS) forecast of 59.796 for the next financial year.

How can I tell whether the Gland Pharma share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Gland Pharma. Over the past six months, the relative strength of its shares against the market has been %. At the current price of ₹2532.85, shares in Gland Pharma are trading at 8.46% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Gland Pharma PE Ratio?

The Gland Pharma PE ratio based on its reported earnings over the past 12 months is 35.1. The shares are currently trading at ₹2532.85.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Gland Pharma?

Gland Pharma's management team is headed by:

P. V. N. Raju - CHM
Ravi Penmetsa - VCH
Who are the major shareholders of Gland Pharma?

Here are the top five shareholders of Gland Pharma based on the size of their shareholding:

Shanghai Fosun Pharmaceutical Group Co Ltd Corporation
Percentage owned: 58.25% (95.3m shares)
Gland Celsus Bio Chemicals Pvt. Ltd. Corporation
Percentage owned: 6.14% (10.0m shares)
R P Advisory Services Pvt.Ltd. Corporation
Percentage owned: 3.77% (6.17m shares)
SBI Funds Management Pvt. Ltd. Investment Advisor
Percentage owned: 3.3% (5.40m shares)
GIC Private Limited Sovereign Wealth Fund
Percentage owned: 2.66% (4.35m shares)
Similar to GLAND
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.